Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.53 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.50 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7924905 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL2124440 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL8806720 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL5379043 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL8526392 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL9008818 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL5379107 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL4069322 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL5395207 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 | |
| Acetic Acid SCHEMBL1685004 | 1.00 | LMNA (0.53) | LMNASLC15A2CAMK2AEGLN1ALKBH5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3695838-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION (AMD) | Katairo GmbH (DE) | 2020-08-19 | — | — | EP | disclosed |
| US-20160279111-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF AMD | TAKEDA GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-20160235724-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF STARGARDT'S DISEASE | KATAIRO GMBH (DE) | 2016-08-18 | — | — | US | disclosed |
| US-9314453-B2 | Tetrahydropyridoethers for treatment of AMD | KATAIRO GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| EP-2742939-A1 | Tetrahydropyridoethers for treatment of age-related macular degeneration (AMD) | Katairo GmbH (DE) | 2014-06-18 | — | — | EP | disclosed |
| EP-2249829-B1 | Tetrahydropyridoethers for treatment of age-related macular degeneration (AMD) | KATAIRO GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-20130131101-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD | KATAIRO GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1970373-A1 | ALICYCLIC HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-7105676-B2 | Tetrahydropyridoethers | ALTANA PHARMA AG (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20040162310-A1 | Tetrahydropyridoethers | ALTANA PHARMA AG. | 2004-08-19 | — | — | US | disclosed |
| US-5965527-A | CYCLOSPORIN A SULFIDED AT THE 3 POSITION BY R-(CH)N-S-BY REACTING A LITHIUM-ACTIVATED DERIVATIVE WITH THE DISULFIDE; SYNERGISTIC MIXTURE WITH A RETROVIRUS VIRICIDE; SIDE-EFFECT REDUCTION; AIDS AND ARC (AIDS RELATED COMPLEX) | RHONE-POULENC RORER, S.A. (FR) | 1999-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | ESR1 879/4885LMNA 4047/4885SLC15A2 2517/4885 |
| US-20040162310-A1 | Tetrahydropyridoethers | CYP7A1, CYP2E1, TPMT | ESR1 571/4885LMNA 3736/4885SLC15A2 2650/4885 |
| US-20130131101-A1 | TETRAHYDROPYRIDOETHERS FOR TREATMENT OF AMD | PTGDR, TBXA2R, NR2E3 | ESR1 239/4885LMNA 4575/4885SLC15A2 2346/4885 |
| US-20160235724-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF STARGARDT'S DISEASE | STARD3, MPST, TPMT | ESR1 1960/4885LMNA 2703/4885SLC15A2 1967/4885 |
| US-20160279111-A1 | TETRAHYDROPYRIDOETHERS FOR THE TREATMENT OF AMD | NR2E3, PTGDR, TBXA2R | ESR1 251/4885LMNA 4558/4885SLC15A2 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.